Page last updated: 2024-08-24

imiquimod and meglumine

imiquimod has been researched along with meglumine in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	4 (66.67)	29.6817
2010's	2 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Alvarez, E; Arevalo, I; Llanos-Cuentas, A; Matlashewski, G; Meng, TC; Miller, R; Najar, E; Ward, B	1
Arévalo, I; Llanos-Cuentas, A; Matlashewski, G; Miranda-Verástegui, C; Ward, BJ	1
Dowlati, Y; Eskandari, SE; Firooz, A; Ghoorchi, MH; Gorouhi, F; Hooshmand, B; Khamesipour, A; Khatami, A; Nassiri-Kashani, M; Rashighi-Firoozabadi, M	1
Arevalo, I; Llanos-Cuentas, A; Matlashewski, G; Pollack, H; Quispe, A; Spaeth, G; Tulliano, G	1
Dobakhti, F; Khalili, G; Khaze, V; Mahmoudzadeh-Niknam, H; Partovi, F	1
Dabiri, S; Javadi, A; Nadji, M; Shamsi Meymandi, M; Shamsi Meymandi, S	1

Trials

4 trial(s) available for imiquimod and meglumine

Article	Year
Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Dec-01, Volume: 33, Issue:11 Topics: Adjuvants, Immunologic; Adolescent; Adult; Aminoquinolines; Antiprotozoal Agents; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Female; Humans; Imiquimod; Infant; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Treatment Outcome	2001
Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2005, May-15, Volume: 40, Issue:10 Topics: Adjuvants, Immunologic; Administration, Topical; Adolescent; Adult; Aged; Aminoquinolines; Antiprotozoal Agents; Child; Child, Preschool; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imiquimod; Infant; Injections, Intravenous; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Peru	2005
Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Archives of dermatology, 2006, Volume: 142, Issue:12 Topics: Adjuvants, Immunologic; Adolescent; Adult; Aminoquinolines; Animals; Antimony; Antiprotozoal Agents; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imiquimod; Leishmania tropica; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Prospective Studies; Single-Blind Method; Treatment Outcome	2006
Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Jun-15, Volume: 44, Issue:12 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Animals; Antiprotozoal Agents; Antirheumatic Agents; Drug Therapy, Combination; Female; Humans; Imiquimod; Injections, Intravenous; Leishmaniasis, Cutaneous; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Pilot Projects; Treatment Outcome	2007

Other Studies

2 other study(ies) available for imiquimod and meglumine

Article	Year
Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection. Iranian journal of immunology : IJI, 2011, Volume: 8, Issue:1 Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Imiquimod; Immunotherapy; Leishmania major; Leishmaniasis; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Treatment Outcome	2011
Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy. Archives of Iranian medicine, 2011, Volume: 14, Issue:4 Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminoquinolines; Animals; Antigens, CD; Antigens, CD1; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; Antiprotozoal Agents; B-Lymphocytes; CD3 Complex; Child; Dermis; Drug Therapy, Combination; Epidermis; Female; Humans; Imiquimod; Iran; Langerhans Cells; Leishmania tropica; Leishmaniasis, Cutaneous; Lymphocyte Count; Macrophages; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Parasite Load; Single-Blind Method; T-Lymphocytes; Young Adult	2011

Article

Year

Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection.

Iranian journal of immunology : IJI, 2011, Volume: 8, Issue:1

Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antiprotozoal Agents; Drug Therapy, Combination; Imiquimod; Immunotherapy; Leishmania major; Leishmaniasis; Meglumine; Meglumine Antimoniate; Mice; Mice, Inbred BALB C; Organometallic Compounds; Treatment Outcome

2011

Comparative histological and immunohistochemical changes of dry type cutaneous leishmaniasis after administration of meglumine antimoniate, imiquimod or combination therapy.

Archives of Iranian medicine, 2011, Volume: 14, Issue:4

Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Aminoquinolines; Animals; Antigens, CD; Antigens, CD1; Antigens, CD20; Antigens, Differentiation, Myelomonocytic; Antiprotozoal Agents; B-Lymphocytes; CD3 Complex; Child; Dermis; Drug Therapy, Combination; Epidermis; Female; Humans; Imiquimod; Iran; Langerhans Cells; Leishmania tropica; Leishmaniasis, Cutaneous; Lymphocyte Count; Macrophages; Male; Meglumine; Meglumine Antimoniate; Middle Aged; Organometallic Compounds; Parasite Load; Single-Blind Method; T-Lymphocytes; Young Adult

2011